Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
0
Weekly News Recap #Phispers
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Trastuzumab Cipla 440 mg
Dosage Form : INJ
Dosage Strength : 440mg
Packaging : 21X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Herceptin 21 mg/ml IV
Dosage Form : INJ
Dosage Strength : 440mg
Packaging : 21X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info :
Registration Country : Australia
Brand Name : Kanjinti
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kanjinti
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Trazimera
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Trazimera
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Trazimera
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Trazimera
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : USA
Brand Name : TRAZIMERA
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 420MG
Packaging :
Approval Date :
Application Number : 761081
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : Australia
Brand Name : Ogivri
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Related Excipient Companies
Excipients by Applications
Dosage Form : Cream / Lotion / Ointment, Emulsion, Gel, Injectable / Parenteral, Suspension, Tablet
Grade : Parenteral, Oral, Topical
Category : Emulsifying Agents, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Dosage Form : Capsule, Cream / Lotion / Ointment, Tablet, Topical Film
Grade : Oral, Topical
Category : Solubilizers
Application : Solubilizers
Excipient Details : A & C's Polysorbate 20 is an excipient which meets the NF monograph.
Dosage Form : Cream / Lotion / Ointment, Emulsion, Gel, Injectable / Parenteral, Suspension, Tablet
Grade : Parenteral, Oral, Topical
Category : Emulsifying Agents, Parenteral, Solubilizers, Surfactant & Foaming Agents, Thickeners and Stabilizers, Topical
Dosage Form : Capsule, Cream / Lotion / Ointment, Tablet, Topical Film
Grade : Oral, Topical
Category : Solubilizers
Application : Solubilizers
Excipient Details : A & C's Polysorbate 20 is an excipient which meets the NF monograph.
Application : Taste Masking
Pharmacopoeia Ref : USP-NF, JP, EP
Technical Specs : Non-reducing disaccharide consisting of two glucose molecules lin...
Ingredient(s) : Trehalose Dihydrate
https://www.pharmacompass.com/radio-compass-blog/fda-okays-50-new-drugs-in-2024-bms-cobenfy-lilly-s-kisunla-lead-pack-of-breakthrough-therapies
https://www.pharmacompass.com/pipeline-prospector-blog/pipeline-prospector-april-2024-indices-dip-amid-muted-q1-results-vertex-acquires-alpine-immune-for-us-4-9-bn
Global Sales Information
Daiichi Sankyo (Switzerland) AG
Dosage Form : Inf Conc
Dosage Strength : 100mg
Price Per Pack (Euro) : 1551.85
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Dosage Form : Inj L?s
Dosage Strength : 1200mg/600mg
Price Per Pack (Euro) : 6431.22
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Dosage Form : Inj L?s
Dosage Strength : 600mg/600mg
Price Per Pack (Euro) : 3719.73
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Dosage Form : Trastuzumab 150Mg 1 Unit Parente...
Dosage Strength : 1 vial groun EV 150 mg
Price Per Pack (Euro) : 1,004.08
Published in :
Country : Italy
RX/OTC/DISCN : Class H
Dosage Form : Trastuzumab 600Mg 1 Unit Parente...
Dosage Strength : 1 vial SC 600 mg/5 ml 6 ml
Price Per Pack (Euro) : 2,871.68
Published in :
Country : Italy
RX/OTC/DISCN : Class H
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 567
2019 Revenue in Millions : 226
Growth (%) : 151
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 6,220
2018 Revenue in Millions : 7,191
Growth (%) : -14
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 572
2020 Revenue in Millions : 567
Growth (%) : 1
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 4,158
2019 Revenue in Millions : 6,729
Growth (%) : -38
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 2,899
2020 Revenue in Millions : 3,956
Growth (%) : -28
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 366
2020 Revenue in Millions : 24
Growth (%) : 1,378
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 126
2020 Revenue in Millions : 115
Growth (%) : 10
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 197
2020 Revenue in Millions : 98
Growth (%) : 101
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 316
2021 Revenue in Millions : 572
Growth (%) : -45
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 122
2021 Revenue in Millions : 126
Growth (%) : -3
Market Place
Reply
19 Jun 2023
Reply
04 Feb 2023
Reply
13 Oct 2022
Reply
03 Feb 2021
Reply
23 Nov 2020
Reply
18 Nov 2020
Reply
16 Nov 2020
Reply
31 Jul 2019
Reply
04 Oct 2017
Reply
09 Aug 2017
Patents & EXCLUSIVITIES
Patent Expiration Date : 2012-06-15
Date Granted : 2005-03-22
Brand Name : HERCEPTIN
Patent Number : 2103059
Filing Date : 1992-06-15
Strength per Unit : 440mg / vial
Dosage Form : Powder for Injection
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2012-06-15
Date Granted : 2005-03-22
Patent Expiration Date : 2020-06-23
Date Granted : 2009-10-06
Brand Name : HERCEPTIN
Patent Number : 2376596
Filing Date : 2000-06-23
Strength per Unit : 440mg / vial
Dosage Form : Powder for Injection
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2020-06-23
Date Granted : 2009-10-06
Patent Expiration Date : 2018-12-10
Date Granted : 2011-04-12
Brand Name : HERCEPTIN
Patent Number : 2311409
Filing Date : 1998-12-10
Strength per Unit : 440mg / vial
Dosage Form : Powder for Injection
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2018-12-10
Date Granted : 2011-04-12
Patent Expiration Date : 2021-05-18
Date Granted : 2011-06-21
Brand Name : HERCEPTIN
Patent Number : 2407556
Filing Date : 2001-05-18
Strength per Unit : 440mg / vial
Dosage Form : Powder for Injection
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2021-05-18
Date Granted : 2011-06-21
Patent Expiration Date : 2017-08-08
Date Granted : 2000-08-08
Brand Name : HERCEPTIN
Patent Number : 1341082
Filing Date : 1989-01-12
Strength per Unit : 440mg / vial
Dosage Form : Powder for Injection
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2017-08-08
Date Granted : 2000-08-08
Patent Expiration Date : 2016-07-23
Date Granted : 2011-10-18
Brand Name : HERCEPTIN
Patent Number : 2226575
Filing Date : 1996-07-23
Strength per Unit : 440mg / vial
Dosage Form : Powder for Injection
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2016-07-23
Date Granted : 2011-10-18
Patent Expiration Date : 2026-03-21
Date Granted : 2016-08-16
Brand Name : HERCEPTIN
Patent Number : 2540547
Filing Date : 2006-03-21
Strength per Unit : 440mg / vial
Dosage Form : Powder for Injection
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2026-03-21
Date Granted : 2016-08-16
Patent Expiration Date : 2026-02-21
Date Granted : 2016-11-15
Brand Name : HERCEPTIN
Patent Number : 2596133
Filing Date : 2006-02-21
Strength per Unit : 440mg / vial
Dosage Form : Powder for Injection
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2026-02-21
Date Granted : 2016-11-15
ABOUT THIS PAGE